Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Practice Patterns in the Diagnosis of Follicular Lymphoma (FL): Report from the National Lymphocare Study (NLCS).

Matthew J. Matasar, MD, MS, Rakhee Saxena, MD, Elaine K. Wong, MD, Daniel A. Filippa, MD, Andrew D. Zelenetz, MD, PhD

Blood (2007) 110 (11): 2613.

https://doi.org/10.1182/blood.V110.11.2613.2613

Published: 2007

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

Adjuvant Dexamethasone (D) ± Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).

Adam D. Cohen, MD, Ping Zhou, MD, PhD, Lillian Reich, MD, Hani Hassoun, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 1163.

https://doi.org/10.1182/blood.V106.11.1163.1163

Published: 2005

Journal Articles

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Tarun Kewalramani, MD, Madhav Dhodapkar, MD, Lisa Drake, Rachel Zimman, Cyrus V. Hedvat, MD, Teruya-Feldstein Julie, MD, Fleisher Martin, phD, Daniel A. Filippa, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2004) 104 (11): 2409.

https://doi.org/10.1182/blood.V104.11.2409.2409

Published: 2004

Journal Articles

Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.

Ping Zhou, MD, PhD, Hugo Castro-Malaspina, MD, Esperanza B. Papadopoulos, MD, James W. Young, MD, Kenneth Miller, MD, Neeta Pandit-Taskar, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Raymond L. Comenzo, MD

Blood (2004) 104 (11): 5113.

https://doi.org/10.1182/blood.V104.11.5113.5113

Published: 2004

Journal Articles

Risk-Adapted Intravenous Melphalan Followed by Adjuvant Dexamethasone (D) and Thalidomide (T) for Newly Diagnosed Patients with Systemic AL Amyloidosis (AL): Interim Results of a Phase II Study.

Adam D. Cohen, Ping Zhou, Lillian Reich, Alice Quinn, Sophia Fircanis, Lisa Drake, Cyrus Hedvat, Julie Teruya-Feldstein, Daniel A. Filippa, Martin Fleisher, Raymond L. Comenzo

Blood (2004) 104 (11): 542.

https://doi.org/10.1182/blood.V104.11.542.542

Published: 2004

Journal Articles

The Follicular Lymphoma International Prognostic Index (FLIPI) Is Superior to WHO/REAL Histological Grade for Identifying High-Risk Patients: A Retrospective Review of the MSKCC Experience in 260 patients with Follicular Lymphoma.

Jeffrey L. Halaas, MD, PhD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Moskowitz Chaya, PhD, Kikkeri N. Naresh, MD, MRCPath, Andrew D. Zelenetz, MD, PhD

Blood (2004) 104 (11): 3268.

https://doi.org/10.1182/blood.V104.11.3268.3268

Published: 2004

Journal Articles

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer, Carol Portlock, David Straus, Ariela Noy, Owen O'Connor, Daniel A. Filippa, Julie Teruya-Feldstein, Alison Gencarelli, Jing Qin, Alyson Waxman, Joachim Yahalom, Craig H. Moskowitz

Blood (2004) 103 (10): 3684–3688.

https://doi.org/10.1182/blood-2003-11-3911

Published: 2004

Journal Articles

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz, Tania Trippett, Eric E. Hedrick, Daniel A. Filippa, Diane Louie, Maria Gonzales, Janine Walits, Nancy Coady-Lyons, Jing Qin, Richard Frank, Joseph R. Bertino, Andre Goy, Ariela Noy, James P. O'Brien, David Straus, Carol S. Portlock, Joachim Yahalom

Blood (2001) 97 (3): 616–623.

https://doi.org/10.1182/blood.V97.3.616

Published: 2001

NARROW

Practice Patterns in the Diagnosis of Follicular Lymphoma (FL): Report from the National Lymphocare Study (NLCS).

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Adjuvant Dexamethasone (D) ± Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.

Risk-Adapted Intravenous Melphalan Followed by Adjuvant Dexamethasone (D) and Thalidomide (T) for Newly Diagnosed Patients with Systemic AL Amyloidosis (AL): Interim Results of a Phase II Study.

The Follicular Lymphoma International Prognostic Index (FLIPI) Is Superior to WHO/REAL Histological Grade for Identifying High-Risk Patients: A Retrospective Review of the MSKCC Experience in 260 patients with Follicular Lymphoma.

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only